HIV Drug Treatment Program: Antiretroviral Treatment, Access and Common Adverse Effects – British Columbia Centre for Excellence

Skip to content

ABOUT
TREATMENT AS
PREVENTION®
HOPE TO HEALTH
RESEARCH & INNOVATION
CENTRE
DRUG TREATMENT
PROGRAMS
RESEARCH

ABOUT
TREATMENT AS
PREVENTION®
HOPE TO HEALTH
RESEARCH & INNOVATION
CENTRE
DRUG TREATMENT
PROGRAMS
RESEARCH

HIV Drug Treatment Program: Antiretroviral Treatment, Access and Common Adverse Effects

April 16, 2021
BC-CfE/FNHA Virtual Doctor of the Day (April 2021)

Junine Toy

Share this video:

PrevPreviousLessons from a new safe supply pilot project at the Hope to Health Centre in the Downtown Eastside

NextHepatitis C Virus: Diagnosis and ManagementNext

Privacy Notice|Privacy Statement|Personal Information Banks|Website Privacy Policy

© 2025 British Columbia Centre for Excellence
St. Paul's Hospital 608–1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
Tel: 604-806-8477 | Fax: 604-806-9044
General inquiries: info@bccfe.ca
Media inquiries: communications@bccfe.ca

(Please do not use any of these email addresses to send personal information or book an appointment.
To book appointments or contact the H2H clinic, please call 604-416-1517 or fax: 604-564-4893.
Do not send your or your client's personal information via email.)

Scroll to Top

CLICK FOR GP-41 DISCONTINUATION NOTICE

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025

Start typing and press enter to search

Search...